Tüdőrák: vizsgálatok itt: Belgium
127 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Hasselt, Liège, Roeselare, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Gent, Hasselt, Jette, Leuven, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisTaking peopleA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Where
- Charleroi, Gent, Hasselt, Liège
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Brussels, Edegem, Ghent, Jette, Leuven
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Brasschaat, Gent, Hasselt, Kortrijk, Leuven, Menen, Namur, Roeselare, Torhout
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Charleroi, Edegem, La Louvière, Liège, Mons
- Életkor
- 18 év and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - 3. fázisNot yet taking people in BelgiumA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Antwerp, Brasschaat, Leuven, Oudergem
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 1. fázisNot yet taking people in BelgiumA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - 2. fázisTaking peopleNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Where
- Charleroi, Gent, Leuven, Roeselare
- Életkor
- 18 év to 95 év
- People
- 630 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Charleroi, Hasselt, Liège, Roeselare, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - 3. fázisTaking peopleA Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Edegem, Gent, Hasselt, Jette, Kortrijk, Libramont-Chevigny, Liège, Yvoir
- Életkor
- 18 év and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00 - No phaseTaking peoplePRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Anderlecht, Edegem, Kortrijk, Liège, Wilrijk
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253 - 3. fázisTaking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Edegem, Ghent, Hasselt, Jette, Kortrijk, Libramont, Yvoir
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - 2/3. fázisNot yet taking people in BelgiumIZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Antwerp, Brussels, Gent, Sint-Niklaas, Yvoir
- Életkor
- 18 év and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Anderlecht, Leuven
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisNot yet taking people in BelgiumA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Edegem, Leuven, Mechelen
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Anderlecht, Ghent, Liège, Wilrijk
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Aalst, Hasselt, Jette, Leuven, Liège, Mons, Roeselare, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Hasselt, Leuven, Liège, Roeselare
- Életkor
- 18 év and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Anderlecht, Charleroi, Hasselt, Leuven, Liège
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 3. fázisTaking peopleEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- Where
- Charleroi, Edegem, Gent, Hasselt, Libramont-Chevigny, Roeselare
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Kortrijk
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Edegem, Leuven, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Edegem, Jette, Libramont-Chevigny, Liège, Mechelen, Roeselare
- Életkor
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Leuven
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00